Close Menu
May 27, 2020
Sponsored by
Discovery Life Sciences

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

Genome Webinar

Vice President of Bioinformatics and Biostatistics, M2Gen

Chief Scientific Officer, Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments. Through construction of comprehensive genotypic, transcriptomic, and phenotypic cohorts of consented cancer patients, M2Gen generates in silico avatars. M2Gen uses this information to accelerate cancer research, clinical trial matching, and development of real-world data comparator cohorts. The breadth and scope of the ORIEN Avatar clinical and molecular data enables the discovery of a wide array of DNA and RNA biomarkers, including those biomarkers associated with response to immuno-oncology agents.

As a partner in the ORIEN Avatar program, Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery, has conducted high-yield, high-quality dual RNA/DNA isolation from formalin-fixed, paraffin-embedded (FFPE) specimens as well as whole-exome sequencing and RNA sequencing services on more than 30,000 tumor and non-tumor samples. These genetic results, sharpened by ORIEN’s clinical data and the significant size of the sample set, accurately elucidate known drivers of cancer, identify new genetic alterations, and reveal novel potential therapeutic targets.

Attend this webinar to learn about:

  • The utility of data from this large, high-quality sample set to guide immunotherapeutic development programs
  • Large-scale sequencing of critical oncology biomarkers, including tumor mutational burden, microsatellite instability, small variants, splice variants, and fusions 
  • Optimized dual extraction methods from a single FFPE block that achieve highly accurate sequencing results across diverse tumor types and normal samples
  • The cancer centers and partners driving M2Gen's ORIEN Avatar program and how you can participate
  • How you can access the ORIEN database to accelerate your oncology drug development studies

 

Sponsored by
Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.